Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo aims to stall ovarian cancer in patients without common DNA repair flaw

NCT ID NCT07694427

Not yet recruiting Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jul 10, 2026 · Last updated Jul 16, 2026 · Updated 2 times

Summary

This phase 3 trial tests whether the experimental drug mocertatug rezetecan (Mo-Rez), given alone or with bevacizumab, can delay cancer progression better than standard observation or bevacizumab alone in people with newly diagnosed advanced ovarian cancer that does not have a homologous recombination deficiency. Participants receive either Mo-Rez, Mo-Rez plus bevacizumab, or active observation with or without bevacizumab. The study measures how long the cancer stays under control and monitors safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
mocertatug rezetecan (Mo-Rez) and bevacizumab
What this could lead to
If successful, this could provide a new maintenance treatment option to delay cancer progression in people with advanced ovarian cancer that lacks a specific DNA repair defect.
What could go wrong
This is an early-phase study, and the experimental drug may not improve outcomes or could cause significant side effects. Results may not apply to all ovarian cancer types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fallopian tube cancer ovarian cancer ovarian neoplasm primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVARIAN NEOPLASMS

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.